Forest to sell Sankyo's Benicar
Forest Laboratories of the USA has entered into a long-term agreementwith Japan's Sankyo to co-promote the latter's Benicar (olmesartan medoxomil), for the treatment of hypertension. Financial terms of the deal were not disclosed.
A New Drug Application for Benicar is presently under review at the US Food and Drug Administration and, if approved, the treatment will be launched during the first half of 2002. Sankyo is filing for approval of olmesartan in Germany and will submit a dossier for Japanese registration next year.
Forest notes that it has been "highly successful in the cardiovascular field" with the calcium antagonist Tiazac (diltiazem), and recently filed an NDA in the USA for lercanidipine, a calcium channel blocker discovered and developed by Italy's Recordati (Marketletter October 8).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze